Immunotherapy updates in advanced hepatocellular carcinoma

Amisha Singh, Ryan J. Beechinor, Jasmine C. Huynh, Daneng Li, Farshid Dayyani, Jennifer B. Valerin, Andrew Hendifar, Jun Gong, May Cho

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. HCC tumor development and treatment resistance are impacted by changes in the microenvironment of the hepatic immune system. Immunotherapy has the potential to improve response rates by overcoming immune tolerance mechanisms and strengthening anti-tumor activity in the tumor microenvironment. In this review, we characterize the impact of immunotherapy on outcomes of advanced HCC, as well as the active clinical trials evaluating novel combination immunotherapy strategies. In particular, we discuss the efficacy of atezolizumab and bevacizumab as demonstrated in the IMbrave150 study, which created a new standard of care for the front-line treatment of advanced HCC. However, there are multiple ongoing trials that may present additional front-line treatment options depending on their efficacy/toxicity results. Furthermore, the preliminary data on the application of chimeric antigen receptor (CAR-T) cell therapy for treatment of HCC suggests this may be a promising option for the future of advanced HCC treatment.

Original languageEnglish (US)
Article number2164
Issue number9
StatePublished - May 1 2021
Externally publishedYes


  • Chimeric antigen receptor
  • CTLA-4
  • Hepatocellular carcinoma
  • Immune checkpoint inhibitors
  • Immunotherapy
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immunotherapy updates in advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this